The willingness of the 4f orbitals of lanthanide metals to participate in chemical reactions is as rare as their presence in Earth's crust. A recent study, however, witnessed the 4f orbital in a ...
Enlaza Therapeutics has launched with $61 million in seed funding to extend to protein-based drugs the option of covalency, a functionality that is now present only in small-molecule medicines. The ...
Challenging previously held views, scientific results show that californium can covalently bond with borate, dramatically altering the electronic characteristics of the californium ion. This research ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Terremoto Biosciences will use a $75 million series A funding round to leverage breakthroughs in chemistry to broaden the covalent drug alphabet available to treat complex diseases. Proceeds from the ...
Enlaza Therapeutics, the first covalent biologic platform company, officially launched today with $61 million in seed funding. The money will be used to advance Enlaza’s unique covalent biologic ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Prof. Hai-Bin Yu from Huazhong University of Science and Technology, Wuhan National High Magnetic Field Center and School of Physics.
Boehringer Ingelheim GmbH has agreed to pay Covant Therapeutics Inc. $10 million for exclusive rights to the latter’s ADAR1-targeting immuno-oncology program. Under the terms of the exclusive research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results